The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

Jesus D. Gonzalez-Lugo, Samarpana Chakraborty, Amit Verma, Aditi Shastri

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments.

Original languageEnglish (US)
Pages (from-to)56-65
Number of pages10
JournalSeminars in hematology
Volume58
Issue number1
DOIs
StatePublished - Jan 2021

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this